Prevalence and Risk Factors of Asymptomatic Hepatitis C Virus Infection in Bangladesh

Mamun-Al-Mahtab, .; Karim, Fazal; Foster, Graham R.; Akbar, SM Fazle; Rahman, Salimur

doi:10.1016/s0973-6883(11)60111-4

Cited by 20 publications

(11 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…61 Data from Bangladesh on HCV prevalence is sparse, but is reported to be low (0·84%). 62 Prevalence is as high as 40% in people who inject drugs with unknown HIV status and 60·7% in those with HIV co-infection; therefore, the burden of HCV is highest in people who inject drugs. 63 Most people who do not inject drugs but are infected with HCV have a history of any injection (treatment by non-qualified village doctors), sharing blades in barber shop, or of circumcision by traditional practitioners.…”

Section: The Lancet Gastroenterology and Hepatology Commissionmentioning

confidence: 99%

“…There have been substantial advances in research on liver diseases in Bangladesh and several epidemiological studies have been published in the past two decades. [56][57][58][59][60][61][62]149,150,[152][153][154][155][156][218][219][220]223,[406][407][408] Still, baseline data on incidence, prevalence, risk factors, natural history, and the changing epidemiology of various causes of liver diseases need to be generated. Studies are needed to develop cheap, accessible, point-of-care testing for HBV and HCV, and on preventive measures and new drug treatments for NAFLD.…”

Section: The Lancet Gastroenterology and Hepatology Commissionmentioning

confidence: 99%

See 1 more Smart Citation

Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission

Sarin

Kumar

Eslam

et al. 2020

The Lancet Gastroenterology & Hepatology

411

303

View full text Add to dashboard Cite

The Asia-Pacific region is home to more than half of the global population and accounted for 62·6% of global deaths due to liver diseases in 2015. 54·3% of global deaths due to cirrhosis, 72·7% of global deaths due to hepatocellular carcinoma, and more than two-thirds of the global burden of acute viral hepatitis occurred in this region in 2015. Chronic hepatitis B virus (HBV) infection caused more than half of the deaths due to cirrhosis in the region, followed by alcohol consumption (20·8%), non-alcoholic fatty liver disease (NAFLD; 12·1%), and chronic infection with hepatitis C virus (HCV; 15·7%). In 2015, HBV accounted for about half the cases of hepatocellular carcinoma in the region. Preventive strategies for viral hepatitis-related liver disease include increasing access to clean drinking water and sanitation. HBV vaccination programmes for neonates have been implemented by all countries, although birthdose coverage is extremely suboptimal in some. Availability of screening tests for blood and tissue, donor recall policies, and harm reduction strategies are in their initial stages in most countries. Many governments have put HBV and HCV drugs on their essential medicines lists and the availability of generic versions of these drugs has reduced costs. Efforts to eliminate viral hepatitis as a public health threat, together with the rapid increase in per-capita alcohol consumption in countries and the epidemic of obesity, are expected to change the spectrum of liver diseases in the Asia-Pacific region in the near future. The increasing burden of alcohol-related liver diseases can be contained through government policies to limit consumption and promote less harmful patterns of alcohol use, which are in place in some countries but need to be enforced more strictly. Steps are needed to control obesity and NAFLD, including policies to promote healthy lifestyles and regulate the food industry. Inadequate infrastructure and insufficient health-care personnel trained in liver diseases are issues that also need to be addressed in the Asia-Pacific region. The policy response of most governments to liver diseases has thus far been inadequate and poorly funded. There must be a renewed focus on prevention, early detection, timely referral, and research into the best means to introduce and improve health interventions to reduce the burden of liver diseases in the Asia-Pacific region. 168 www.thelancet.com/gastrohep Vol 5 February 2020The Lancet Gastroenterology & Hepatology Commission accounted for 108 276 (8·2%) of the total liver-related deaths in the region in 2015, compared with 929 (1·2%) of 72 437 in the USA and 4032 (0·3%) of 197 179 in Europe. Deaths in the Asia-Pacific region represented three-quarters of the global total number of deaths due to acute viral hepatitis. In 2015, the region accounted for three-quarters of the global total number of deaths related to acute HBV, almost two-thirds of those due to acute hepatitis A infection, and almost 80% of those due to acute hepatitis E infection. Of all deaths du...

show abstract

Section: The Lancet Gastroenterology and Hepatology Commissionmentioning

confidence: 99%

Section: The Lancet Gastroenterology and Hepatology Commissionmentioning

confidence: 99%

Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission

Sarin

Kumar

Eslam

et al. 2020

The Lancet Gastroenterology & Hepatology

411

303

View full text Add to dashboard Cite

show abstract

“…It is estimated that Bangladesh harbors about 8 million chronic hepatitis B virus (HBV) and chronic hepatitis C virus (HCV)-infected people. 2 3 Also, there is frequent outbreak of viral acute hepatitis those are caused by hepatitis A virus (HAV) and hepatitis E virus (HEV). Also, the numbers of patients with noncommunicable disease like nonalcoholic fatty liver diseases (NAFLDs) are on increasing trend.…”

Section: Introductionmentioning

confidence: 99%

Distribution of Liver Disease in Bangladesh: A Cross-country Study

Rahman

et al. 2013

Euroasian Journal of Hepato-Gastroenterology

Self Cite

View full text Add to dashboard Cite

Introduction ‘Hepatology’, as an independent discipline of medical science, has recently been established in Bangladesh. The aim of this study was to formulate the distribution of pattern of liver diseases in this country.Materials and methods In this retrospective study, data regarding patients of liver diseases from the seven different administrative divisions of Bangladesh between January 2012 and 2013 were compiled.Results The study included 59,227 patients (age ranged 15-95 years). Majority of the patients were males (67.9%). Although all patients appeared at the department of hepatology, 13.2% were diagnosed with liver diseases, but a vast majority of patients (77.35%) were suffering from nonulcer dyspepsia or irritable bowel syndrome. Patients with liver diseases were mostly suffering from chronic liver diseases (CLDs) (37 -69%). Complication of CLD, like hepatic encephalopathy, was less frequent in regions with better healthcare system. Nonviral infections, like liver abscess and biliary ascarisis, were not uncommon. Acute hepatitis was another very common entity and contributed to approximately 20% cases.Conclusion This study provides insight about heterogeneous distribution pattern of liver diseases in different regions of Bangladesh.How to cite this article: Rahman S, Ahmed MF, Alam MJ, Debnath CR, Hoque MI, Hussain MM, Shamsul Kabir AKM, Karim MF, Khondokar FA, Mahtab MA, Masud MG, Mollick MKU, Moben AL, Noor-E-Alam SM, Podder PK, Raha AK, Rahim MA, Rashid MHO, Zaki KMJ, Akbar SMF. Distribution of Liver Disease in Bangladesh: A Cross-country Study. Euroasian J Hepato-Gastroenterol 2014;4(1):25-30.

show abstract

“…The included 15 studies with a total sample size of 60 496 reported the prevalence of hepatitis B in Bangladesh and the characteristics of all studies are presented in Table 1. All the included articles [14][15][16][17][18][19][20][21][22][23][24][25][26][27][28] were cross-sectional studies and conducted throughout the period ranging from 1995 to 2017. The smallest sample size was 130 [14] and the largest sample size was 43 213 [26].…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

The prevalence of hepatitis B virus infection in Bangladesh: a systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

Despite the availability of an effective vaccine, hepatitis B virus (HBV) infection is one of the major public health problems worldwide, mostly in developing countries. This systematic review and meta-analysis were performed to estimate the pooled prevalence of HBV infection in Bangladesh. We systematically searched various electronic databases to retrieve relevant studies published until April 2021. A total of 15 studies were met the inclusion criteria and included in the meta-analysis. The pooled estimated prevalence of HBV infection in the general population of Bangladesh from 1995 to 2017 was 4.0% [95% confidence interval (CI) 3.0-5.1]. The results of subgroup analysis revealed that the prevalence of hepatitis B was higher in females than males [odds ratio (OR) 1.20, 95% CI 0.48-2.97, P = 0.70], people of age <25 years had a higher prevalence than people of age >25 years (OR 1.25, 95% CI 0.72-2.17, P = 0.42) and married people had a higher prevalence than unmarried/single people (OR 2.16, 95% CI 1.51-3.10, P < 0.0001). The Egger's test statistics (P = 0.584), Begg and Mazumdar's rank correlation test (P = 0.054) indicated the absence of publication bias. This study analysis reported a low intermediate prevalence of HBV infection (4%) in Bangladesh, which is currently higher than the global prevalence of HBV infection (3.5%).

show abstract

Prevalence and Risk Factors of Asymptomatic Hepatitis C Virus Infection in Bangladesh

Cited by 20 publications

References 12 publications

Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission

Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission

Distribution of Liver Disease in Bangladesh: A Cross-country Study

The prevalence of hepatitis B virus infection in Bangladesh: a systematic review and meta-analysis

Contact Info

Product

Resources

About